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Introduction
To date, severe acute respiratory syndrome (SARS-
CoV-2) coronavirus has infected about 87 million people 
worldwide. First reported in Wuhan, China, in mid 
December 2019, it soon swept across China and the rest 
of the world (1). On January 30, 2020, the World Health 
Organization (WHO) declared the SARS-CoV-2 outbreak 
a public health emergency. However, a few months later, 
owing to its unstoppable spread, it was labeled as a global 
pandemic in a virtual media briefing on coronavirus 
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disease 2019 (COVID-19) (2). During the first wave of the 
pandemic, endeavouring to thwart the spread of the disease, 
governments across the globe imposed state lockdowns. 
Such drastic measure completely upended social and 
economic activities. Indeed, most productive activities, 
including academic teaching and research, were suspended. 
Making matters worse was the sudden surge in SARS-
CoV-2 patients needing medical assistance, ranging from 
primary care to intensive care. In the wake of such scenario, 
all international health systems were soon overwhelmed. 
Indeed, many hospital buildings were converted into 
COVID-19 facilities to withstand the substantial influx of 
infectious cases (3). Moreover, the massive recruitment of 
energy and healthcare human resources needed to cope with 
the pandemic determined a series of delays in diagnosis and 
treatments, as well as suspension of follow-up care for many 
patients with chronic conditions (4). Consequently, whereas 
medical diagnostic activities, classified as non-urgent, were 
significantly modified, novel workflows for the management 
of oncological patients were adopted by many clinics to 
ensure adequate clinical triage.
The field of predictive molecular pathology was also 
swept in this scenario. Pinto et al. reported that molecular 
tests decreased by 27% in the period from March 16 to April 
15, 2020, compared to the same period in 2019. Stunningly, 
liquid biopsy testing for the detection of epidermal growth 
factor receptor (EGFR) exon 20 p.T790M decreased by 
about 67% (5). Interestingly, in a recent study, which 
compared our molecular testing volume during lockdown 
with that of the corresponding period in 2019, Malapelle 
et al. reported not only a reduction in liquid biopsy samples 
but also a change in the laboratory organization. For 
example, fully automated technologies, such as the Idylla 
platform, were introduced to offset limited staff and work 
hours (6). One of the most important lessons our laboratory 
learned from the first wave of COVID-19 is that however 
drastic government restrictions may be during a health 
emergency, no patient should ever be left behind. Now that 
the world is the midst of a second wave of the COVID-19 
pandemic, a possible alternative to using conventional 
tissue or cytological samples for molecular predictive 
purposes could be the adoption of liquid biopsy. Indeed, 
being a rapid, valid, and minimally invasive approach, it is 
now increasingly being used in everyday clinical practice 
to identify predicting biomarkers in a high percentage of 
lung cancer patients (7). In particular, circulating tumor 
DNA (ctDNA) consists of small fractions of whole cell-free 
DNA (cfDNA) that are released into the bloodstream by 
tumor cells through either active or passive mechanisms. As 
of today, even though several promising biomarkers have 
been isolated from torrent blood (cfDNA, extracellular 
vesicle, miRNA), only ctDNA is currently approved for 
the administration of targeted therapies (8). However, 
ctDNA has yet to be approved as a predictive biomarker for 
treatment selection in non-small cell lung cancer (NSCLC) 
patients. In this review, we evaluate the role of liquid biopsy 
in managing lung cancer patients during the still ongoing 
COVID-19 healthcare emergency (Figure 1).
We present the following article, as a result of a deep 
analysis of the recent international literature published in 
English on PubMed in the last six months focused on the 
impact of SARS-CoV-2 on the management of lung cancer 
patients, focusing the attention on the role of liquid biopsy, in 
accordance with the Narrative Review Reporting Checklist 
(available at: https://dx.doi.org/10.21037/med-21-9).
Liquid biopsy: general considerations
Studies have shown that ctDNA has a very short half-life 
and circulates in the bloodstream at very low concentrations. 
Therefore, appropriate pre-clinical management of ctDNA 
in liquid biopsy is crucial to preserve its stability (9). In this 
regard, sample collection and storage are two fundamental 
pre-analytical steps. For example, when BD Vacutainer® 
blood collection tubes are used, it is mandatory to clarify 
plasma and store the supernatant at −20 ℃ within 2 hours 
from blood draw. However, when commercially available 
preservative tubes are used, stability can be maintained 
for much longer periods of time, even up to seven days 
from blood draw. Another important pre-analytical step is 
sampling time. In fact, ctDNA concentration is higher in 
advanced than in early stage cancer patients (10). Moreover, 
plasma is generally preferred to serum for clinical 
applications (11-13).
In spite of these few technical issues, liquid biopsy is 
a valid alternative to other types of conventional tissue 
and cytological samples in the advanced stages of cancer 
to select patients for targeted therapies. Indeed, NSCLC 
patients harboring EGFR- sensitizing mutations in liquid 
biopsy benefit from EGFR tyrosine kinase inhibitors (TKIs) 
administration. For instance, our laboratory recently 
showed an overall EGFR mutation detection rate of 8% 
from ctDNA prospectively analyzed and extracted from 
the plasma of advanced NSCLC patients (14,15). In all 
instances, all EGFR mutations were also further confirmed 
by an orthogonal digital polymerase chain reaction (dPCR) 
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assay. Evidence for the utility of plasma ctDNA as a 
predictive biomarker in NSCLC patients has also emerged 
from the ASSES clinical trial. In this trial, the authors 
compared plasma ctDNA yield with that from tissue and 
cytological samples. Notably, findings from this trial 
confirmed the clinical usefulness of plasma-derived ctDNA 
samples, as shown by the good concordance rate with as 
many as 1,162 matched tissue/cytology samples (16).
Equally important,  l iquid biopsy has also been 
implemented in clinical trials to assess the development of 
drug resistance. For instance, the AURA trial demonstrated 
the efficiency of liquid biopsy specimens in routine clinical 
practice to identify EGFR exon 20 p.T790M resistance 
point mutation after first- or second-line EGFR TKIs (17). 
Similarly, Hochmair et al. showed a higher number of EGFR 
exon 20 p.T790M resistant point mutations in liquid biopsy 
samples than in corresponding tissue specimens (18). The 
comparable efficiency between this approach and tissue 
biopsy was also confirmed by another study showing that all 
plasma samples captured EGFR exon 20 p.T790M mutations, 
whereas only 55% of matching tissue samples did (19).
In addition to detecting mutations in the advanced stages 
of the disease, in recent years, liquid biopsy has also shown 
promise in detecting tumor-associated mutations in the very 
early stages of NSCLC. For example, Pérez-Ramírez et al. 
reported an overall detection rate in 80% of ctDNA from 
early stage cancer patients, despite low levels of ctDNA in 
the bloodstream (20). Similarly, Chen et al. demonstrated 
the utility of liquid biopsy in patients with stages IA-
IIIA NSCLC, highlighting once again the feasibility of 
ctDNA identification in early stage NSCLC patients (21). 
Moreover, Sorber et al. demonstrated that the application 
of high sensitive multiplexed PCR and next generation 
sequencing platforms to liquid biopsy enables higher 
detection rates of cancer driver mutations in the early 
stages of the disease (22). These results clearly endorse the 
incorporation of this approach in routine clinical practice 
for early screening and detection of NSCLC and other 
types of solid tumors.
Circulating tumor cells are also emerging as a valuable 
tool for monitoring disease progression and treatment 
response to first line TKI EGFR treatments in NSCLC 
patients. Indeed, several investigators have turned their 
attention to the possibility of using liquid biopsy to assess 
minimal residual disease (MRD) after TKI treatment. 
In this setting, identification of molecular alterations in 
ctDNA may represent a good strategy to assist clinicians 
in choosing the best therapeutic strategy in a short amount 
of time. For example, Chaudhuri et al. analyzed 255 liquid 
biopsy samples from 40 NSCLC first line patients and 
Figure 1 During the current COVID-19 pandemic, liquid biopsy may represent a valid alternative to tissue samples for lung cancer early 
detection, genotyping, and monitoring. cfDNA, cell-free DNA; COVID-19, coronavirus disease 2019; CTC, circulating tumor cell.
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54 samples from healthy donors (23). Overall, ctDNA 
was detectable in 94% of blood samples from NSCLC 
patients. Likewise, Chae et al., in a review on the recent 
advances in sequencing technology and ctDNA analysis, 
concluded that the combination of sequencing technology 
and plasma ctDNA analysis can help clinicians monitor 
patients’ disease burden after surgical resection while 
assessing molecular targets, without having to recur 
to additional surgical treatments (24). In the future, 
liquid biopsy may also play a pivotal role in guiding the 
administration of targeted therapies in several other types 
of solid tumors (25).
In addition to blood samples, the presence of ctDNA 
has also been detected in various body fluids, such as pleura 
effusions, saliva, urine, and cerebrospinal fluids (26). For 
example, one study by Du et al. showed that quantitative 
PCR was able to detect EGFR mutations in 591 pleural 
effusions from NSCLC patients. Another study showed 
similar results in saliva (27). In particular, the authors 
successfully isolated genetic material from the saliva of 
patients diagnosed with NSCLC, pancreatic cancer, breast 
cancer, gastric cancer, and head and neck squamous cell 
carcinoma (28). Still, Pu et al. obtained a perfect EGFR 
mutation concordance between 17 saliva samples and 
corresponding resected samples from NSCLC patients (29).
Urinary ctDNA liquid biopsy also holds a great 
diagnostic potential in a variety of cancers. As evidenced 
by Jain et al., ctDNA isolated from urine can be useful not 
only to detect urological-neoplasms, but also to monitor 
populations at increased risk for other types of cancers, like 
nasopharyngeal carcinoma, gastric cancer, NSCLC, and 
hepatocellular carcinoma (30).
Undoubtedly, plasma ctDNA, together with other types 
of non-blood body fluids, constitutes a clinically valid tissue 
surrogate, especially in hard-to reach primary tumors or 
in metastatic tumors whose origin is uncertain, However, 
as of today, implementing liquid biopsy on a large scale in 
diagnostic routine remains a challenge. Indeed, a major 
hurdle is the high sensitivity and specificity technologies 
required for molecular analyses. Among these, real-time 
PCR (RT-PCR) is the most widely adopted laboratory 
technology in the clinical setting (31). Another equally valid 
technology is digital PCR (dPCR). Impressively, this assay 
can identify and quantify different mutations at the single-
molecule level. For example, Malapelle et al. showed that 
dPCR is highly sensitive for EGFR mutations in NSCLC 
patients (32). A similar line of research, comparing the 
sensitivity of dPCR with that of an ultra-deep massive 
parallel sequencing, confirmed the efficiency of dPCR in 
detecting clinically relevant mutations, as evidenced by the 
high concordance rate (91.5%) between the two assays (33). 
Another valuable technology is NGS technology. Based on 
massive and parallel sequencing, this technology enables 
molecular cytopathologists to analyze different gene targets 
for different patients in a single run (34,35). Interestingly, 
several commercial approaches are currently available 
to analyze clinically relevant mutations in liquid biopsy 
specimens. For instance, Heeke et al. compared their in-
house platform with an outsourced platform to analyze 
ctDNA from NSCLC patients. To this aim, they analyzed 
blood samples from 24 untreated non-squamous cell lung 
carcinoma patients with their in-house approach, namely the 
Oncomine cfTNA assay (Thermo Fisher Scientific, Waltham, 
MA, USA). Concomitantly, the same analysis was conducted 
by an external testing center with the Foundation Liquid test 
(Foundation Medicine, Cambridge, MA, USA) (36). The 
data showed an overall concordance between the two panels 
of 73%, suggesting that liquid biopsies can be efficiently 
analyzed by both in-house approaches and outsourced 
assays. In a study by Li et al. NSCLC, plasma samples were 
prospectively collected and analyzed by ultra-deep NGS 
approach by using a hybrid panel covering 37 lung cancer-
related genes (37). The Authors showed a concordance 
of 98% between the NGS approach and digital droplet 
PCR (ddPCR) for EGFR and Kirsten Rat Sarcoma Viral 
Oncogene Homolog (KRAS) mutation analysis. Inspired 
by these results, a number of laboratories have developed 
custom panels able to satisfy their local diagnostic requests. 
For instance, Schwartzberg et al. recently validated a 17-
gene liquid biopsy NGS panel, yielding a positive predictive 
value of 98.9% (38). Remarkably, in another experience, 
Malapelle et al. painstakingly described the development 
and testing efficiency of a custom NGS panel for cfDNA 
analysis extracted from serum and plasma specimens of 79 
NSCLC patients, demonstrating a sensitivity of 90.5% and 
a specificity of 100% (39).
Liquid biopsy: pre-analytical and analytical 
issues
The COVID-19 pandemic has significantly modified our 
lives, including molecular laboratory practice (40). SARS-
CoV-2 belongs to risk group 3 human pathogen because of 
its ability to generate a life-threatening infection for which 
satisfactory prophylaxis and treatment are still limited 
(41-43). Consequently, the need to ensure social distancing 
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and security measures has led to a reduced laboratory staff. 
As a result, many molecular cytopathology laboratories 
have had to rapidly shift from more complex and time-
consuming technologies to less complex and fully 
automated platforms, which generally require less hands-
on time and expertise (6,41-43).
Undoubtedly, laboratory professionals, owing to the 
nature of their work, are at a higher risk of being exposed 
to viruses in normal times, let alone in times of a pandemic. 
Therefore, since the beginning of the current pandemic, 
several security measures have been adopted by laboratories 
worldwide to prevent the spread of the virus in the work 
environment. For example, guidelines recommend that 
samples from the airways, which may contain viable and 
transmissible viruses, be handled very carefully to avoid 
contagion (44-46). Regarding liquid biopsy samples, 
however, there is still little evidence on whether they 
may also represent a possible means of transmission (47). 
Under all circumstances, studies recommend the adoption 
of procedures equivalent to Biosafety Level (BSL) 2 to 
reduce the risk of spreading the infection among laboratory 
staff (46,48). In addition, adequate personal protective 
equipment (PPE) should be worn whenever fresh or unfixed 
samples are handled (49). Equally important, laboratory 
procedures prone to generate droplets (including sample 
preparation, aliquoting of material, centrifugation and 
vortexing) should be avoided as much as possible. However, 
should these highly risky procedures be unavoidable, class 
I or, preferably class II biosafety cabinets (BSCs) (48,50,51) 
are strongly recommended. Last but not least, all surface 
areas should be thoroughly and adequately disinfected with 
chemical substances with well-known activity against SARS-
CoV-2 (48).
Abiding by these security measures is paramount not 
only to prevent laboratory professionals from contracting 
the infection but, equally important, to ensure that patients 
with diagnosed or suspected cancers continue to receive all 
the necessary care and services without the risk of being 
exposed to COVID-19. Indeed, as strongly recommended 
by the European Society for Medical Oncology (ESMO), 
lung cancer molecular analysis and treatments should be 
continued without any delays (52), mainly because such 
delays could not only worsen patients’ conditions but also 
create unmanageable backlogs in treatments and diagnoses.
On the other hand, the “draconian” measures adopted 
by state governments since the beginning of the pandemic 
to tackle the relentless spread of COVID-19, have reduced 
hospital admissions of lung cancer patients (53). In addition, 
the so-called “distraction effect”, due to the recruitment of 
healthcare figures to cope with the spread of COVID-19, has 
reduced the number of requests for molecular testing (54). 
Consequently, the limited access to diagnostic procedures 
has determined scarce availability of tissue samples from lung 
cancer patients, primarily because of the risks associated with 
airway tissue samples (55-57).
In this healthcare emergency, it is no wonder that liquid 
biopsy has recently gained increasing attention compared 
to more conventional tissue and cytology techniques. For 
example, it may be a valid option to reduce the potential 
risks of contagion among lung cancer patients by limiting the 
number of hospital stays. It could also help cytopathologists 
overcome some of the shortcomings associated with tissue 
biopsies, including the unavailability of tissue specimens for 
molecular purposes. Further, it could minimize the risk of 
handling potentially infectious airway tissue samples, thereby 
avoiding a potential spread of the virus among staff (58). 
Besides these advantages, recent research has also fully 
validated the efficiency of this approach in detecting 
cancer driver mutations both in early and in late stage lung 
cancer patients. This is a paramount advantage when one 
considers the widespread postponement of cancer screening 
programs. In this regard, it has been widely demonstrated 
that the integration of ctDNA and tumor tissue analysis 
into routine clinical practice may increase the detection of 
clinical relevant biomarkers useful for targeted treatment 
administration (59). In addition, the adoption of the “blood-
first” approach may significantly shorten time to treatment, 
counterbalancing the possible delays associated with 
COVID-19 containment measures (60). Oddly, although 
Malapelle et al. reported no significant differences in the 
number of tested samples for molecular predictive purposes 
between 2019 and 2020, they did observe a significant 
reduction in liquid biopsies analysis (6). Plausibly, the lower 
volume of processed liquid biopsy samples was ascribable, 
on one hand, to patients’ reluctance to visit hospitals for 
fear of contracting the virus, and, on the other hand, to the 
drop in scheduled hospital appointments to ensure social 
distancing. Intriguingly, to circumvent this limitation, Rolfo 
et al. recently proposed a shift in the current diagnostic 
workflow of liquid biopsy samples, emphasizing the need 
of implementing home phlebotomy services and/or mobile 
units for blood draws and transport, followed by a central 
NGS analysis of ctDNA (58). Finally, this new approach 
could also be applied to monitor the efficacy of systemic 
treatments, including targeted drugs, and to modify the way 
clinical trials are carried out, especially during the current 
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pandemic (58).
Liquid biopsy: clinical considerations
COVID-19 patients with comorbidities, including 
cardiopathies, diabetes, and cancer, may be at higher risk 
of developing life-threatening complications like cute 
respiratory distress syndrome (ARDS) and multiple organ 
failure (61). Cancer patients, especially those undergoing 
treatment, seem to fare worse than others (62). The reason is 
that tumors and the adverse effects of oncological treatments 
can compromise patients’ immune systems, rendering 
them more severely susceptible to COVID-19 infection 
and complications (63). Indeed according to a nationwide 
analysis of Chinese cancer patients during the COVID-19 
outbreak, cancer patients were more vulnerable to severe 
events than cancer-free patients, as evidenced by the higher 
number of oncological patients in intensive care units 
needing mechanical ventilation. In addition, more severe 
events were seen in patients who had been on oncological 
active treatment for at least a month before the infection (62). 
Consistently, Zhang et al also showed that cancer patients 
affected by COVID-19, who had received antitumor therapy 
within 14 days of COVID-19 diagnosis, had poorer outcomes 
than the otherwise healthy patients (64).
Management and diagnosis of lung cancer patients 
during the current pandemic have been much more 
challenging than ever before in both intensive and a primary 
care settings. The reason is that COVID-19 common 
presenting symptoms (e.g., dyspnea, fatigue, fever, cough, 
and anosmia) are also very frequently found in lung cancer 
patients (65). Moreover, symptom overlap between thoracic 
malignancies and COVID-19 can complicate cancer early 
diagnosis in patients presenting acute symptoms (65). As 
mentioned earlier, in this challenging subset of SARS-
CoV-2 infection, the various comorbidities associated with 
lung cancer can significantly affect COVID-19-related 
mortality risk. Among these events are cardiovascular 
disease, diabetes, smoking habits, and chronic obstructive 
pulmonary disease (COPD) (66). Thus, lung cancer patients 
are particularly vulnerable to suffering from respiratory 
failure due to SARS-CoV-2-related pneumonia (67,68). 
Specifically, in a large multicenter observational study (the 
TERAVOLT trial), a higher mortality risk was statistically 
and clinically associated with age, smoking status, 
chemotherapy treatment, and the concomitant presence of 
comorbidities (68).
Hence, although this unprecedented global scenario has 
significantly affected the routine clinical management of 
lung cancer patients, it behooves health care professionals 
to continue providing personalized cancer treatments along 
with the best therapeutic strategies while minimizing as 
much as possible the risk of infection among lung cancer 
patients. Accordingly, different oncology societies have 
released several recommendations and guidelines. For 
instance, some guidelines recommend delaying cancer 
treatments on the basis of patients’ clinical status, prognosis, 
and tumor characteristics, and adopting telemedicine 
consultations instead of in-person visits (69). In view 
of prioritizing oncological treatments during a global 
pandemic, guidelines recommend at-home oral therapies 
instead of standard chemotherapy infusion to prevent 
patients from getting infected while being treated (70,71). 
Additionally, it is recommended that all elective surgeries be 
rescheduled to prioritize essential cancer surgeries (72).
The COVID-19 pandemic has had dramatic consequences 
on molecular testing for thoracic malignancies. One need 
only consider the decreased number of collected samples 
seen since the beginning of the pandemic. Indeed, access to 
diagnostic procedures, crucial for cancer diagnosis, has been 
limited in an effort to prevent the spread of COVID-19 
infection in healthcare settings. In this context, molecular 
predictive pathology practice has seen a notable reduction 
especially in the NSCLC setting, where tumor genotyping is 
essential and mandatory for selective treatment (6,73).
The metastatic NSCLC setting epitomizes the value 
of implementing liquid biopsy in routine clinical practice, 
even more so during a health crisis, given the greater 
burden and the higher detection rate of ctDNA typically 
found in the advanced stages of the disease (12). Liquid 
biopsy, specifically cfDNA analysis, is a rapidly expanding 
and minimally invasive analysis of translational cancer 
research. Impressively, being a highly versatile tool in 
the management of lung cancer, liquid biopsy can assist 
clinicians in selecting targeted treatments, monitoring 
treatment response, and detecting drug resistance 
mechanisms, without posing the risks of contagion. For 
instance, studies have shown that in combination with NGS 
technologies, it can successfully identify therapeutically-
targetable alterations, thereby improving molecularly-
guided oncological treatments (74).
Therefore, in this unprecedented health emergency, the 
integration of liquid biopsy in routine clinical practice is 
crucially important to minimize the danger of SARS-CoV-2 
infection for oncological patients and to reduce surgical 
procedures in patients with insufficient or unavailable 
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cancer tissue for molecular analysis. Moreover, the 
implementation of plasma NGS jointly with tumor tissue 
genotyping has been demonstrated to increase mutation 
detection up to 26% compared with standard-of-care 
approaches (75). Moreover, the identification of circulating 
biomarkers has also be shown to guide treatment planning 
for a large number of patients potentially eligible for 
targeted oral agents. Concomitantly, it has proven highly 
efficient in monitoring patients undergoing active cancer 
treatments (76).
Interestingly, liquid biopsy can also be exploitable in 
the clinical trial setting. Indeed, being less invasive, easier 
to handle, and faster to process than conventional tissue 
and cytological specimens, it can help clinicians accelerate 
screening and enrollment of larger numbers of patients who 
could benefit from entering clinical trials. By the same token, 
integrating liquid biopsy in the current workflow may enable 
patients to start oncological treatment much sooner (60).
The feasibility of using liquid biopsy in clinical trials 
is particularly relevant in today’s health crisis. Several 
studies have indeed well-established that the routine 
conduction of clinical trials has been considerably altered 
since the introduction of the drastic containment measures. 
However, because this unprecedented clinical scenario is 
rapidly evolving, there is an urgent need to find dynamic 
alternatives to the ways clinical studies and sample 
collection are carried out. All things considered, a variation 
in regular diagnostic management for advanced lung cancer 
patients is highly recommended.
More specifically, before the pandemic, liquid biopsy 
rapidly emerged as a potential diagnostic tool able to 
detect and assess the earlier stages of the disease as well 
as post-treatment molecular residual disease (77). With 
the advent of the pandemic, however, cancer prevention 
has been overshadowed by the various response measures 
against the spread of COVID-19. Indeed, the pandemic 
has led to the suspension of cancer screening services, 
delayed diagnosis, and, ultimately, reduced overall cancer 
survival (78). In this context, liquid biopsy could be used to 
circumvent the delays compromising traditional screening 
programs while reducing the risk of viral contagion during 
standard procedures. Notwithstanding, future research on 
the possible applications of liquid biopsy in the early-stage 
setting is keenly warranted.
Conclusions
COVID-19 pandemic has significantly modified our lives 
and overall medical practice (79-81). In these unprecedented 
times, liquid biopsy may represent a valid and less time-
consuming diagnostic approach than conventional tissue 
and cytological specimens. This primarily because it 
can help reduce the danger of viral spread by avoiding 
invasive surgical procedures in those NSCLC patients 
with insufficient or unavailable cancer tissue for molecular 
analysis.  Furthermore, this new approach may be 
significantly useful not only to help oncologists choose 
targeted treatments according to the molecular profile of 
each patient’s tumor, but also to restart the many suspended 
clinical trials. Thus, considering today’s turbulent times and 
despite the practical advantages that liquid biopsy may offer, 
further studies are needed for the application of this non 
invasive approach in everyday clinical practice, as well as in 
clinical trials, to streamline tumor genotyping and targeted 
therapies.
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